evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

8 questions · 8 findings · 3 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 62.5%High 3 · 37.5%

Intervention not reported

Discontinuations due to adverse events · patients with rheumatoid arthritis

The intervention leads to higher discontinuations due to adverse events (high certainty).

1 finding from 1 review

Febuxostat 80 mg/day vs placebo

Withdrawals due to adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs placebo

Withdrawals due to adverse events · patients with chronic cout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat 80 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs placebo

Withdrawals due to adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Discontinuation of medication due to adverse events · patients with rheumatoid arthritis

Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in discontinuations due to adverse events Analysis 6.3 compared with methotrexate monotherapy (moderate certainty).

1 finding from 1 review